A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
S
Samir Gupta, MD
Primary Investigator
Not Recruiting
18-100 years
All
Phase
3
1 Location
Overview
This trial will study putative therapeutics in a hospitalized population with moderate to severe COVID-19.
Description
Participants will be randomly assigned to receive placebo or an experimental study drug.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
COVID-19
-
Age: Between 18 Years - 100 Years
-
Gender: All
Individuals at least 18 years of age admitted to the hospital with symptoms suggestive of COVID-19.
Women who are pregnant or breastfeeding will not be eligible.
Updated on
01 Aug 2024.
Study ID: 2005800939